StockNews.AI
NVNO
StockNews.AI
193 days

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

1. VenoValve trial shows 78% sustained clinical improvement after 24 months. 2. Average improvement of 8.2 points in rVCSS indicates robust patient benefit.

2m saved
Insight
Article

FAQ

Why Bullish?

The sustained positive results in the trial may enhance investor confidence, similar to past biotech gains on favorable study outcomes.

How important is it?

Positive clinical trial results often lead to increased stock performance, particularly in medical technology sectors like NVNO.

Why Long Term?

Long-term patient benefit could attract more investors, reflecting trends seen in companies with consistent positive trial data.

Related Companies

NVNO
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort.

Related News